RAC - Charts & Price Action, page-6962

Always enjoy your posts, @W3Booster. Thank you for your time.

I'm seeing a symmetrical triangle play out on the daily and a cup and handle on the weekly. I don't put a lot of weight into my charting skills and much prefer FA to drive my thoughts on price movements (probably why I'm useless at entries). As such, I suspect that it will not be long before we see the upper resistance levels broken and all time high cleared.



There are many lines of evidence that I draw from to come to this conclusion, like the baseline valuation I completed not long ago indicating that other first-in-class or best-in-class drugs achieved an average buyout price of AUS $9.4B ($55 ps; 170M SOI). I also consider the massive amount of FTO-directed preclinical and clinical data to come out over the next 12 months.



What I have not discussed is when I think the City of Hope 2.0 paper will be released to market. Having looked through Jianjun Chen's published papers (1), I picked out papers that seemed to follow on from the last. My estimation is that we can expect the City of Hope 2.0 paper around September, which is about 6 weeks away from the current date. Clearly, the actual release data may be earlier or later than this estimate. The original City of Hope paper that discovered Bisantrene was extremely detailed and of remarkable quality, and so I expect the second one to match that.



I believe that the next run may be the longest and largest, as it will coincide directly with independent research completed by an internationally recognised research group, 7 FTO-directed preclinical programs, and 4 clinical programs with a focus on FTO expression or MoA. Those who have invested more because they recognise the amount of data about to be generated over the next 12-18 months and the likelihood of FTO inhibition in historic clinical data are setting themselves up very nicely in my opinion (It's exactly what I am doing).

1 https://www.cityofhope.org/people/jianjun-chen